Cala Health has received a $50m growth capital commitment from investment firm Trinity Capital, setting the company up with funds to expand its neuromodulation therapy for tremor management in patients with essential tremor and Parkinson’s disease.
Cala kIQ,which was US Food and Drug Administration (FDA) cleared in 2023, is a wearable transcutaneous afferent patterned stimulation (TAPS) system to help patients manage hand tremors caused by essential tremor and Parkinson’s disease. Cala kIQ Plus, the next-generation version of the wearable, which adds new therapy modes and adaptive calibration designed to further personalise TAPS treatment for tremor control, obtained FDA clearance on 15 April 2026.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Worn on the wrist and prescribed by physicians for use at home, Cala’s device measures a patient’s unique tremor pattern and delivers individualised nerve stimulation to counteract tremors. The overall aim of this therapy is to help restore patients’ ability to perform daily activities such as writing, eating, and drinking.
“We are pleased to partner with the Trinity team to optimise our capital structure,” said Cala CEO Deanna Harshbarger. “This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS therapy to impact the lives of essential tremor and Parkinson’s disease patients.”
According to GlobalData analysis, the global neuromodulation device market is projected to reach a valuation approaching $11bn in 2033, up from around $6bn in 2023.
Other FDA-cleared devices for tremor management include Fasikl’s Felix NeuroAI and Insightec’s Exablate Neuro platform which uses focused ultrasound waves to precisely target and ablate tissue deep within the brain to control the symptom.
Around 10 million people live with Parkinson’s disease worldwide, yet no disease-modifying therapies (DMT) for the disease currently exist. The current standard of care (SoC) on the pharmaceutical side for symptom management is the use of levodopa. According to expert observers, funding barriers and outdated clinical trial approaches remain as critical barriers to innovation in the Parkinson’s disease space.
